Multiscale Research Institute of Complex Systems & Jingan District Central Hospital of Shanghai, Fudan University, Shanghai, China.
Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China.
Front Immunol. 2022 Jul 27;13:951107. doi: 10.3389/fimmu.2022.951107. eCollection 2022.
Although numerous clinical trials have been implemented, an absolutely effective treatment against coronavirus disease 2019 (COVID-19) is still elusive. Interleukin-22 (IL-22) has attracted great interest over recent years, making it one of the best-studied cytokines of the interleukin-10 (IL-10) family. Unlike most interleukins, the major impact of IL-22 is exclusively on fibroblasts and epithelial cells due to the restricted expression of receptor. Numerous studies have suggested that IL-22 plays a crucial role in anti-viral infections through significantly ameliorating the immune cell-mediated inflammatory responses, and reducing tissue injury as well as further promoting epithelial repair and regeneration. Herein, we pay special attention to the role of IL-22 in the lungs. We summarize the latest progress in our understanding of IL-22 in lung health and disease and further discuss maneuvering this cytokine as potential immunotherapeutic strategy for the effective manage of COVID-19.
尽管已经实施了许多临床试验，但针对 2019 年冠状病毒病（COVID-19）的绝对有效治疗方法仍难以捉摸。白细胞介素-22（IL-22）近年来引起了极大的关注，使其成为白细胞介素-10（IL-10）家族中研究最多的细胞因子之一。与大多数白细胞介素不同，由于受体的限制表达，IL-22 的主要影响仅在成纤维细胞和上皮细胞上。许多研究表明，IL-22 通过显著改善免疫细胞介导的炎症反应，减少组织损伤，进一步促进上皮修复和再生，在抗病毒感染中发挥关键作用。在此，我们特别关注 IL-22 在肺部中的作用。我们总结了我们对 IL-22 在肺部健康和疾病中的最新认识，并进一步讨论了操纵这种细胞因子作为 COVID-19 有效管理的潜在免疫治疗策略。
